CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 484 enrolled
Drug / intervention
Serlopitant High Dose +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02975206
NCT02975206Phase 2Completed

A Randomized, Double-Blind, Placebo Controlled Study Of The Efficacy, Safety, And Tolerability Of Serlopitant For The Treatment Of Pruritus In Adults And Adolescents With A History Of Atopic Dermatitis

Vyne Therapeutics Inc.·interventional·Posted Nov 29, 2016·Updated May 20, 2021

In Brief

A Phase 2 clinical trial evaluating Serlopitant High Dose, Placebo Oral Tablet, and 1 other intervention for Pruritus and Atopic Dermatitis. Completed, enrolled 484 participants across 52 sites.

Detailed Summary

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 29, 2016
Enrollment StartNov 1, 2016
Primary CompletionJan 16, 2018
Study CompletionFeb 23, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.6 years ago

Interventions

Serlopitant High Dosedrug

serlopitant tablets - high dose

Placebo Oral Tabletdrug

placebo tablet

Serlopitant Low Dosedrug

serlopitant tablets - low dose